Pharmaceutical company Merck is planning to separate its human health business into two divisions, according to a Monday report from The Wall Street Journal. The move is intended to alleviate operational pressure resulting from the patent expiration of its top-selling drug, Keytruda.
One division will focus on cancer drugs, including Keytruda, while the other will handle the sales of non-cancer medications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.